Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Hubert Rehrauer
University of Zurich
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
97
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Combination of the Novel Raf Dimer Inhibitor Brimarafenib with the Mek Inhibitor Mirdametinib is Effective Against Nras Mutant Melanoma
Number of pages: 45
Posted: 09 Sep 2024
Flavia L. Tellenbach
,
Luzia L. Seiler
,
Mark Johnson
, Hubert Rehrauer,
Prachi Schukla
,
Julia Martinez-Gomez
,
Corinne I. Stoffel
,
Adeela Kamal
,
Reinhard Dummer
,
Mitchell Paul Levesque
and
Ossia M. Eichhoff
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
, University of Zurich,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
, University Hospital Zurich - Department of Dermatology, University Hospital Zurich - Department of Dermatology and
affiliation not provided to SSRN
Downloads
97
(704,534)
View PDF
Download
Abstract:
Metastatic melanomaRAF dimer inhibitorMAPK pathwaydual inhibitionNRAS mutation
Feedback
